EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging strategies for cancer therapy by ATR inhibitors

Kimiyoshi Yano, Bunsyo Shiotani iD

Cancer Science · 2023-07 · 114 (7) · 2709-2721

DOI: 10.1111/cas.15845 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 15.05.2023. Verfasst von Kimiyoshi Yano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Tokyo, Japan. Hauptthemen laut MEDLINE: DNA Damage, Neoplasms. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA replication stress (RS) causes genomic instability and vulnerability in cancer cells. To counteract RS, cells have evolved various mechanisms involving the ATR kinase signaling pathway, which regulates origin firing, cell cycle checkpoints, and fork stabilization to secure the fidelity of replication. However, ATR signaling also alleviates RS to support cell survival by driving RS tolerance, thereby contributing to therapeutic resistance. Cancer cells harboring genetic mutations and other changes that disrupt normal DNA replication increase the risk of DNA damage and the levels of RS, conferring addiction to ATR activity for sustainable replication and susceptibility to therapeutic approaches using ATR inhibitors (ATRis). Therefore, clinical trials are currently being conducted to evaluate the efficacy of ATRis as monotherapies or in combination with other drugs and biomarkers. In this review, we discuss recent advances in the elucidation of the mechanisms by which ATR functions in the RS response and its therapeutic relevance when utilizing ATRis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageNeoplasmsHumansAtaxia Telangiectasia Mutated ProteinsProtein Kinase InhibitorsSignal TransductionCell Cycle CheckpointsDNA ReplicationCheckpoint Kinase 1

Stichwörter der Autor:innen

ATR inhibitorATR kinaseDNA replication stressbiomarkercancer therapyreplication stress tolerance

Substanzen

Ataxia Telangiectasia Mutated ProteinsProtein Kinase InhibitorsCheckpoint Kinase 1ATR protein, human

Autor:innen und Institutionen

  • Laboratory of Genome Stress Signaling, National Cancer Center Research Institute, Tokyo, Japan.

ORCID-Profile: Bunsyo Shiotani

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Yano, K., & Shiotani, B. (2023). Emerging strategies for cancer therapy by ATR inhibitors. Cancer Science, 114(7), 2709-2721. https://doi.org/10.1111/cas.15845

Vancouver

Yano K, Shiotani B. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Science. 2023;114(7):2709-2721. doi:10.1111/cas.15845

BibTeX
@article{Yano2023,
  author = {Yano, Kimiyoshi and Shiotani, Bunsyo},
  title = {Emerging strategies for cancer therapy by ATR inhibitors},
  journal = {Cancer Science},
  year = {2023},
  volume = {114},
  number = {7},
  pages = {2709--2721},
  doi = {10.1111/cas.15845}
}
Kostenlos starten →